Notice NOT-HL-21-031 from the NIH Guide for Grants and Contracts

Notice NOT-DA-21-020 from the NIH Guide for Grants and Contracts

Notice NOT-CA-21-112 from the NIH Guide for Grants and Contracts

Notice NOT-CA-21-113 from the NIH Guide for Grants and Contracts

Notice NOT-CA-21-114 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-251 from the NIH Guide for Grants and Contracts. This is a reissue of the Emerging Global Leader Program (K43) to align with the clinical trials policy.

Funding Opportunity PAR-21-252 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA PAR-. The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (http://data.worldbank.org/about/country-classifications/country-and-lending-groups , including low-income, lower-middle-income, and upper-middle-income countries). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Funding Opportunity Announcement (FOA) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors.

£60,000 - £80,000 depending on experience + competitive benefits package: Singular Talent: Do you want to joint he network-driven drug discovery revolution? If yes, then apply your computational expertise here! United Kingdom

Funding Opportunity RFA-DA-22-040 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.

Funding Opportunity RFA-DA-22-028 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support human and animal research on the pharmacokinetic (PK) and pharmacodynamic (PD) effects of ?9-tetrahydrocannabinol (THC) that is present in cannabis and cannabis products.

Funding Opportunity RFA-DA-22-039 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support human and animal research on the pharmacokinetic (PK) and pharmacodynamic (PD) effects of ?9-tetrahydrocannabinol (THC) that is present in cannabis and cannabis products.

Negotiable: SRG: An opportunity for an experienced Molecular Biologist to join an established organisation working at the forefront of drug discovery. Greater Manchester, England

Competitive with benefits, subject to skills & experience: The Francis Crick Institute: The Crick Genome Function Laboratory led by Greg Findlay investigates how mutations lead to phenotypes by developing new functional genomics methods. London (Greater) (GB)

Notice NOT-OD-21-184 from the NIH Guide for Grants and Contracts

Competitive with benefits, subject to skills and experience: The Francis Crick Institute: We are seeking a talented postdoctoral researcher to help uncover the biological processes that lead to inflammatory bowel disease (IBD). London (Central), London (Greater) (GB)

Funding Opportunity RFA-NS-22-009 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications that address the unmet need to detect cognitive impairment, including dementia, in large and diverse populations seen in primary care across the United States, including in health disparities populations, when a patient, relative, or care provider indicates concern. Proposed clinical paradigms should utilize tools that are simple to use, standardized, and ideally take five minutes or less to administer in a primary care clinical setting.

Funding Opportunity PAR-21-330 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.

Notice NOT-CA-21-115 from the NIH Guide for Grants and Contracts

Notice NOT-AT-21-018 from the NIH Guide for Grants and Contracts

Notice NOT-AT-21-017 from the NIH Guide for Grants and Contracts